Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Net Loans Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Fortress Biotech (FBIO) Cash from Discontinued Operations (2018)

Fortress Biotech has reported Cash from Discontinued Operations over the past 1 years, most recently at 5737000.0 for Q4 2018.

Quarterly results put Cash from Discontinued Operations at 5737000.0 for Q4 2018, changed N/A from a year ago — trailing twelve months through Dec 2018 was 1785000.0 (changed N/A YoY), and the annual figure for FY2018 was 1785000.0, up 56.96%.
Cash from Discontinued Operations for Q4 2018 was 5737000.0 at Fortress Biotech, up from 2226000.0 in the prior quarter.
Over the last five years, Cash from Discontinued Operations for FBIO hit a ceiling of 5737000.0 in Q4 2018 and a floor of 7367000.0 in Q2 2018.